Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Familial Primary Pulmonary Hypertension

• A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
• 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
• The Safety, Tolerability, and Pharmacokinetics of TPN171H Tablets in Patients With Pulmonary Arterial Hypertension
• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
• Anti-CD20 Antibodies for Treatment of SLE-PAH
• Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
• Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants
• Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
• A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
• Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
• Consistency of Electrical Cardiometry and Pulmonary Artery Catheter
• Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
• Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
• Empagliflozin in Pulmonary Arterial Hypertension
• PET Image in PAH Patients
• Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
• Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension
• Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
• Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
• A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
• Dapagliflozin in Pulmonary Arterial Hypertension
• A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
• Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
• A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
• Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
• A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants
• Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
• Apabetalone for Pulmonary Arterial Hypertension
• A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality
• Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study
• Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
• Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients
• Single-Dose, Open Label Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
• A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)
• A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)
• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (STELLAR)
• Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
• A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension
• Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension
• A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
• Positioning Imatinib for Pulmonary Arterial Hypertension
• Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH
• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
• Oral CXA-10 in Pulmonary Arterial Hypertension
• A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
• Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
• Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension
• CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
• Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606
• Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
• Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
• Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
• Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension
• A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
• Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
• Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
• Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension
• Upfront Combination Pulmonary Arterial Hypertension Therapy
• Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
• Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
• Olaparib for PAH: a Multicenter Clinical Trial
• A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
• Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
• Effects of DHEA in Pulmonary Hypertension
• Fluoxetine in Pulmonary Arterial Hypertension (PAH) Trial
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
• Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
• Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric
• Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
• Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
• Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
• Subcutaneous Elafin in Healthy Subjects
• EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
• Effect of BIA 5 1058 on Cardiac Repolarization
• Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
• PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
• A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
• Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension
• Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
• Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension
• (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
• Spironolactone Therapy in Chronic Stable Right HF Trial
• A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
• The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension
• Olaparib for PAH: a Pilot Study
• Goal Oriented Strategy to Preserve Ejection Fraction Trial
• Pulmonary Hypertension and Anastrozole Trial
• Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
• A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)
• Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
• Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension
• Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
• Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
• Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)
• Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
• A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
• Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
• [18F]FES PET/CT in PAH
• Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
• Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
• Crossover Study From Macitentan or Bosentan Over to Ambrisentan
• An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
• Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
• Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
• Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)
• Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
• Acute Effects of Benzbromaron on the Pulmonary Circulation
• Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension
• Right Ventricular Metabolism in Pulmonary Arterial Hypertension
• A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
• Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
• Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
• Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
• Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
• A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
• A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
• Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
• Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
• Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
• Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients
• Beta-blockers in Pulmonary Arterial Hypertension
• Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
• Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide
• Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)
• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
• Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension
• Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
• Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)
• A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
• Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
• Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
• The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
• Selonsertib in Adults With Pulmonary Arterial Hypertension
• Safety of Terbogrel in Patients With Primary Pulmonary Hypertension
• Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension
• Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure
• Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)
• Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
• OPsumit USers Registry
• Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
• Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
• A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
• Effects of Oral Sildenafil on Mortality in Adults With PAH
• Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
• Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
• Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
• Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension
• Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
• 11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
• Hydroxyurea in Pulmonary Arterial Hypertension
• Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)
• A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
• Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)
• Beraprost-314d Added-on to Tyvaso® (BEAT)
• Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
• Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
• (-)-Epicatechin and Pulmonary Arterial Hypertension
• To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers
• Iron Status and Hypoxic Pulmonary Vascular Responses
• Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument
• Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
• Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE
• A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
• Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
• A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)
• Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
• Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
• A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
• Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
• Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
• Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05
• A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
• Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
• Bosentan and Pulmonary Endothelial Function
• Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
• Spironolactone for Pulmonary Arterial Hypertension
• Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate
• Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost
• FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
• Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
• Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
• Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension
• Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain
• The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects
• Remodulin® to Oral Treprostinil Transition
• An Open Label Access Study For Subjects Who Completed A1481156
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
• Inhaled Treprostinil for PAH: Open-label Extension
• Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
• Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
• Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
• Anastrozole in Patients With Pulmonary Arterial Hypertension
• Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
• Revatio Portal-Pulmonary Arterial Hypertension Trial
• A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
• Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
• Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
• Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension
• Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)
• A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
• Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
• Effects of Apelin on the Lung Circulation in Pulmonary Hypertension
• IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients
• Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
• Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain
• Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension
• Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
• Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
• Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients
• Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
• Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
• Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
• Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
• Efficacy of Ventavis Used in Real-life Setting.
• Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)
• An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
• FUTURE 3 Study Extension
• Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
• Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
• Treprostinil Combined With Tadalafil for Pulmonary Hypertension
• Iron Deficiency In Pulmonary Hypertension
• Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
• Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
• Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
• The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
• Drug Interaction Between Ritonavir And Sitaxsentan
• Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
• Beta-blockers in i-PAH
• A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
• Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension
• Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
• A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
• Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
• A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
• Ranolazine and Pulmonary Hypertension
• A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers
• Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
• Nitric Oxide, GeNO Nitrosyl Delivery System
• Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine
• The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
• Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
• ACT-293987 in Pulmonary Arterial Hypertension
• Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
• Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
• Epoprostenol for Injection in Pulmonary Arterial Hypertension
• Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)
• Tezosentan in Patients With Pulmonary Arterial Hypertension
• Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide
• Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
• Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension
• Tezosentan in Pulmonary Arterial Hypertension
• Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
• Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)
• Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
• A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
• A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
• An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
• A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin
• Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
• Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
• Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
• Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
• Effect of Food on the Pharmacokinetics of Oral Treprostinil
• To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
• Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
• Early Therapy of Pulmonary Arterial Hypertension
• Ventavis® Registry Protocol
• Imatinib (QTI571) in Pulmonary Arterial Hypertension
• Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
• Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
• Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
• Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
• A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
• BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
• Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
• Insulin Resistance in Pulmonary Arterial Hypertension
• Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers
• Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
• A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
• A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
• Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
• Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
• Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
• An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
• A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
• Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension
• Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
• Iloprost Power Disc-15 in Pulmonary Arterial Hypertension
• The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension
• Iloprost Power 15 in Pulmonary Arterial Hypertension
• Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
• Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
• Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
• Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
• Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
• A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
• Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
• Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
• Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
• Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
• Pharmacogenomics in Pulmonary Arterial Hypertension
• Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients
• Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
• A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
• A Study to Evaluate GSK1325760A - a Long-Term Extension Study
• Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
• Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
• Hemodynamic Response After Six Months of Sildenafil
• Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
• Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension
• Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
• Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
• Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
• 6R-BH4 Pulmonary Arterial Hypertension Study
• Combination Therapy in Pulmonary Arterial Hypertension
• To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
• Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
• Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
• Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
• A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
• BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
• FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
• FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
• Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
• Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
• Bosentan in Children With Pulmonary Arterial Hypertension
• Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
• Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
• Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
• Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
• The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
• Bosentan in Treatment of Pulmonary Arterial Hypertension
• Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
• Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension
• A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
• Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension
• A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
• Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
• PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
• Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)
• A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension
• Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
• ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
• Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
• Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension
• A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
• Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
• Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
• Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension
• Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension